Lindenwold Advisors INC Purchases Shares of 8,245 ResMed Inc. $RMD

Lindenwold Advisors INC bought a new position in shares of ResMed Inc. (NYSE:RMDFree Report) in the second quarter, Holdings Channel reports. The fund bought 8,245 shares of the medical equipment provider’s stock, valued at approximately $2,127,000. ResMed makes up approximately 1.1% of Lindenwold Advisors INC’s portfolio, making the stock its 27th largest holding.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Global X Japan Co. Ltd. lifted its holdings in shares of ResMed by 121.4% during the first quarter. Global X Japan Co. Ltd. now owns 124 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 68 shares in the last quarter. Golden State Wealth Management LLC grew its position in ResMed by 384.8% in the first quarter. Golden State Wealth Management LLC now owns 160 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 127 shares during the last quarter. Zions Bancorporation National Association UT bought a new position in ResMed in the first quarter valued at about $45,000. Groupe la Francaise bought a new stake in shares of ResMed during the first quarter worth about $45,000. Finally, CVA Family Office LLC grew its holdings in shares of ResMed by 29.8% during the first quarter. CVA Family Office LLC now owns 209 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 48 shares during the last quarter. Institutional investors and hedge funds own 54.98% of the company’s stock.

Wall Street Analysts Forecast Growth

RMD has been the topic of several research reports. KeyCorp boosted their price target on ResMed from $274.00 to $298.00 and gave the stock an “overweight” rating in a report on Friday, August 1st. UBS Group raised ResMed to a “strong-buy” rating in a research note on Tuesday, September 16th. Stifel Nicolaus upped their target price on ResMed from $240.00 to $270.00 and gave the stock a “hold” rating in a research report on Friday, August 1st. Royal Bank Of Canada upped their target price on ResMed from $294.00 to $300.00 and gave the stock an “outperform” rating in a research report on Friday, August 1st. Finally, William Blair raised ResMed to a “strong-buy” rating in a research report on Friday, August 1st. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $294.20.

Get Our Latest Report on RMD

ResMed Stock Down 2.1%

RMD stock opened at $271.96 on Friday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.53 and a current ratio of 3.44. The company has a market capitalization of $39.69 billion, a price-to-earnings ratio of 28.60, a PEG ratio of 1.87 and a beta of 0.83. ResMed Inc. has a fifty-two week low of $199.92 and a fifty-two week high of $293.81. The stock has a fifty day moving average of $278.51 and a 200-day moving average of $255.46.

ResMed (NYSE:RMDGet Free Report) last posted its quarterly earnings results on Thursday, July 31st. The medical equipment provider reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.47 by $0.08. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.33 billion. ResMed had a return on equity of 25.62% and a net margin of 27.22%.The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.08 EPS. As a group, equities research analysts predict that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, September 18th. Shareholders of record on Thursday, August 14th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend was Thursday, August 14th. This is a boost from ResMed’s previous quarterly dividend of $0.53. ResMed’s payout ratio is presently 25.24%.

Insider Buying and Selling at ResMed

In other ResMed news, Director John Hernandez sold 2,575 shares of ResMed stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $287.10, for a total transaction of $739,282.50. Following the completion of the transaction, the director owned 4,045 shares of the company’s stock, valued at $1,161,319.50. The trade was a 38.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael J. Farrell sold 8,009 shares of ResMed stock in a transaction dated Tuesday, October 7th. The shares were sold at an average price of $282.85, for a total value of $2,265,345.65. Following the transaction, the chief executive officer directly owned 467,792 shares of the company’s stock, valued at $132,314,967.20. The trade was a 1.68% decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,743 shares of company stock valued at $5,284,514 in the last quarter. 0.71% of the stock is currently owned by corporate insiders.

ResMed Company Profile

(Free Report)

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.

Featured Articles

Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMDFree Report).

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.